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ABSTRACT 
The endospore-forming Bacillus subtilis has been used as probiotics over the last 50 years. However, little 
is known on how Bacillus spp act in the gut compared to other well-characterized probiotics such as lactic 
acid bacteria. It is believed that the competitive exclusion of pathogens results from different mode of action 
notably  the  production  of  antimicrobial  compounds  such  as  bacteriocins.  Here,  we  report  the 
characterization  of  the  unexpected  ability  of  a  gut-associated  B.  subtilis  BSP1  to  synthetize  the  cyclic 
bacteriocin subtilosin A at high level. Our findings suggest that the BSP1 phenotype could be related, at 
least in part, to a subsequent increased expression level of the subtilosin A biosynthetic gene cluster sbo-alb 
in response to a higher activity of the stationery and sporulation master regulator Spo0A. 
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1. INTRODUCTION 
Necrotic enteritis is an enterotoxemia disease caused 
by Clostridium perfringens in chicken, turkey and ducks. 
It leads to the development of necrotic lesions in the gut 
wall, resulting in death of poultry (Timbermont et al., 
2011).  This  is  a  multifactorial  disease,  whose 
epidemiology  and  pathogenesis  are  not  yet  fully 
understood  (Garcia  and  Heredia,  2011).  Worldwide, 
necrotic enteritis is considered one of the most threatening 
emerging diseases in the broiler industry. Global economic 
losses as a consequence of necrotic enteritis outbreaks have 
been  estimated  at  over  $2  billion  per  year,  largely 
attributable  to  medical  treatments  and  impaired  growth 
performance (Lee et al., 2001). Medical treatments consist 
most  of  the  time  of  antibiotic  utilization.  However, 
emergence of antibiotic-resistant strains of C. perfringens 
highlights  the  need  of  alternative  solutions  to  overcome 
these sanitary problems. 
Probiotics  are  live  microbes,  which  when 
administrated  in  adequate  amounts  confer  a  health 
benefit  to  the  host  (Cutting,  2011).  Their  use  as  feed 
additives  in  the  stockbreeding  industry  is  of  attracting 
increased  attention  as  a  cost-effective  alternative  to 
antibiotics  to  control  animal  diseases  (Reuter,  2001). 
Previous studies have suggested that Bacillus subtilis can 
be used to increase and maintain beneficial bacteria in 
the  intestine  (Hoa  et  al.,  2000;  Thirabunyanon  and 
Thongwittaya, 2012). B. subtilis is an endospore-forming 
bacterium  whose  spore  consists  of  several  protective 
layers  surrounding  the  nucleoid  in  the  spore  core 
(Henriques  and  Moran,  2007).  Due  to  their  structural 
organization, spores are extremely resistant to external 
chemical  and  physical  mugging  and  are  partly Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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responsible  for  their  exceptional  longevity  in  the 
environment (Henriques and Moran, 2000). In regards to 
their non-pathogenic status, Bacillus subtilis have been 
used as probiotics over the last 50 years. As they might 
form  heat-stable  spores,  Bacillus  spp.  present  several 
advantages  over  other  probiotic  bacteria  such  as 
Lactobacillus  spp.  Indeed,  Bacillus  spores  present  a 
longer  shelf  life  at  room  temperature  and  could  cope 
with the low pH of gastric barrier. Spores probiotics are 
being extensively used as dietary supplements in human 
or as growth promoters and competitive agents in animal 
feed. In the past, it was assumed that most aerobic spore-
formers belong to the B. subtilis species (Cutting, 2011). 
However,  several  of  these  strains  were  found  to  be 
misidentified  and  to  carry  multidrug  resistances  or  to 
harbor toxic genes (Hoa et al., 2000; Duc et al., 2006). 
This highlights the need  for a  more rigorous  selection 
and a deeper strain characterization in order to obtain a 
safer utilization. Compared to lactic acid bacteria, little is 
know  about  how  Bacillus  spp  act  as  probiotic.  It  is 
believed  that  the  competitive  exclusion  of  pathogens 
results  from  one  or  more  modes  of  action,  including 
immune  exclusion,  competition  for  adhesion  sites  or 
production  of  antimicrobial  compounds,  such  as 
bacteriocins  (Patterson  and  Burkholder,  2003;  
Barbosa  et  al.,  2005).  Bacteriocins  are  ribosomally 
synthetized  proteins  that  elicit  bactericidal  activity, 
usually against closely related species (Klaenhammer, 
1993).  Some  bacteriocins,  the  so-called  lantibiotics 
(class  I  bacteriocins),  can  undergo  posttranslational 
modificationsa  and  contain  thioether  amino  acid 
lanthionine  or  methyllanthionine  (Bierbaum  and  Sahl, 
2009; Fickers, 2012) whereas class II bacteriocins do not 
(Nissen-Meyer et al., 2009). 
It has been suggested in the past, that animal probiotics 
should  preferentially  originate  directly  from  the  target 
animal  microflora,  as  their  use  would  be  ethically  more 
acceptable and potentially more effective than exogenous 
strains. In that sense, Barbosa and collaborators isolated 237 
presumptive  gut-associated  spore  former  Bacillus  spp 
strains from broiler chicken feces (Barbosa et al., 2005). For 
thirty-one  of  them,  16S  rRNA  gene  sequence  analysis 
revealed that they belong to B. subtilis, Bacillus pumilus, 
Bacillus  licheniformis,  Bacillus  megaterium,  as  well  as 
Bacillus  cereus,  of  which  some  strains  are  considered 
pathogens  because  of  their  association  with  foodborne 
illness. All isolates efficiently sporulate in laboratory and 
the  resulting  spores  were  tolerant  to  simulated 
gastrointestinal tract conditions. Importantly, some of these 
isolates also exhibited an antimicrobial activity against food 
spoilage and/or pathogenic organisms such as Clostridium 
perfringens,  Staphylococcus  aureus  and  Listeria 
monocytogenes. The study of Barbosa et al. (2005) suggests 
that  some  of  the  Bacillus  spore-former  isolates  have  the 
potential  to  persist  in  or  transiently  associated  with  the 
complex  gut  ecosystem.  In  the  present  work,  we  further 
characterized the antimicrobial activity of one of these B. 
subtilis isolates, the so-called BSP1. 
2. MATERIALS AND METHODS 
2.1. Bacterial  Strains,  Culture  Media  and 
General Genetic Techniques 
Plasmid, recombinant B. subtilis and bacteria isolated 
from swine intestinal content are listed in Table 1 and 2, 
respectively.  Oligonucleotide  primers  used  for  PCR 
amplification are listed in Table 3. Standard molecular 
genetic techniques were used (Sambrook et al., 1989). 
Restriction enzymes and T4 DNA ligase were obtained 
from  Fermentas  (St.  Leon-Rot,  Germany).  Genomic 
DNA  was  purified  using  the  Wizard  genomic 
purification  kit  (Promega,  Madison,  WI,  USA).  PCR 
amplifications  were  performed  with  Fideli  Taq 
polymerase  (USB  Corporation,  Cleveland,  OH,  USA) 
and amplified fragments were purified with the Qiagen 
purification  kit  (Hilden,  Germany).  The  culture  media 
were  Luria-Bertani  broth  (LB  broth,  Sigma-Aldrich), 
brain-heart  infusion  (BH  broth,  Difco)  and  Difco 
Sporulation Medium (DSM). 
 
Table 1. Activity spectrum of cell-free supernatant of BSP1 on 
bacteria isolated from swine intestinal content
1 
Strain  Antimicrobial activity
2 
Gram negative 
Escherichia coli 0.94  - 
Escherichia fergusonii  - 
Klebsiella pneumonia  - 
Salmonella typhimurium PF3127  - 
Salmonella Derby PF2709  - 
Salmonella enteritidis PF1338  - 
Enterobacter cloacae  - 
Gram positive 
Staphylococcus hyicus  ++ 
Streptococcus bovis  - 
Enterococcus faecium  - 
Enterococcus durans  + 
Lactobacillus salivarus  - 
Lactobacillus fermentum  - 
Lactobacillus acidophilus  - 
Clostridium perfingens  + 
Clostridium perfringens P41  +++ 
Listeria monocytogenes HCIP59.53  + 
Listeria ivanovii DCIP78.42  +++++ 
Listeria ivanovii DCIP107777  +++++ 
1All  strains  are  from  DSM  Nutritional  Products  collection, 
Basel, Switzerland 
2The different score reflect the different degree of inhibition. +, 
halo of growth inhibition; multiple +, increased diameter of the 
inhibition zone; -, no growth inhibition Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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Table 2. Strains and plasmids used in this study 
Strain or plasmid  Relevant Genotype / Phenotype  Reference 
B.  subtilis 
strains 
PY79  Prototrophic  Zeigler et al. (2008) 
168  Prototrophic  Zeigler et al. (2008) 
BSP1  Poultry gastrointestinal isolate #200  Barbosa et al. (2005) 
BSP1 sboAX  sboAX ::Cm
R  This study 
168 sboAX   sboAX ::Cm
R   His study 
AH7496 PY79  derivative (sboA::PsboAPY79-cfp /Cm
R)  This study 
AH7497  BSP1 derivative (sboA::PsboABSP1-cfp /Cm
R)  This study 
Plasmids 
pCS57  bla PsboA PY79-cfp cat   This study 
pCS58   bla PsboA BSP1-cfp cat  This study 
pDR200   bla cfp kan   Doan et al. (2005) 
pMS38   bla cat   Serrano and Henriques 
    (Unpublished results) 
pRFP121   bla cat   Fickers
 (Unpublished results) 
unpublished results 
 
Table 3. Oligonucleotide primers used in this study 
Primer name  Sequence (5´ - 3´)  Restriction sites 
Sbo1  CTTCATTTGTTCCGCAATGTTCA 
Sbo2  TTTTGGCCCAGTGGGCCAATTGAATCCTCCCTTTTTTTGTT  SfiI 
Sbo3  TTTTGGCCCCAGCGGCCTGAATCATATGTATAGGGGATGGTATTTT  SfiI 
Sbo4  CAAGTTTGGGCAAAAGAGCCTTTTC 
sboA-380F  GGGGTACCCGATGACTTCTTGGTTTCCG  KpnI 
sboACFP+38R  GTTCCTCCTTATGTAAGCTTGGCTCCGATCGAGCATGTTG 
CFP-24F  AAGCTTACATAAGGAGGAAC 
CFP+750R  CGCGGATCCTTACTTATAAAG  BamHI 
Restriction sites are underlined 
 
2.2. Production,  Purification  and 
Characterisation of Subtilosin A 
For  subtilosin  A  production,  BSP1  was  grown  in 
shake  flasks  for  18  h  in  LB  medium  at  37°C. 
Antimicrobial  compounds  were  extracted  from  the 
culture  supernatant  by  hydrophobic  chromatography 
using  Amberlite  XAD-16  (Sigma,  50  gr  per  liter  of 
culture medium). After washing steps (five bead volume 
each)  with  MilliQ  water  and  MilliQ  water-methanol 
mixture  (25-75%  v/v),  subtilosin  A  was  eluted  in  two 
bead  volume  of  methanol  and  concentrated  by  rotary 
evaporation  under  vacuum.  Further  purifications  were 
conducted  by  Reverse  Phase  Highpressure  Liquid 
Chromatography (RP-HPLC) on an Xterra RP18 column 
(4.6´150 mm, 3.5  m, Waters, Milford, MA, USA) in a 
water-acetonitrile  eluent  system  containing  0.1%  of 
trifluoroacetic acid (waters). Molecules were eluted at a 
flow rate of 1  ml  min
-1  in  a 40  min  gradient ranging 
from 0 to 100% of acetonitrile. Eluted compounds were 
collected and those corresponding to subtilosin A were 
identified by means of antimicrobial activity tests plates 
using Listeria ivanovii as a sensitive strain (Halimi et al., 
2010).  Molecular  weight  determination  of  the  purified 
antilisterial peptide (50 ng) was determined by Matrix-
Assisted  Laser  Desorption  Ionization-Time  of  Flight 
(MALDI-TOF) mass spectrometry in positive mode on a 
Ultraflex II apparatus (Bruker Daltonics) using α-cyano-
β-hydroxycinnamic  acid  as  a  matrix.  MALDI-TOF 
analyses  were  performed  at  the  GIGA-Proteomics 
facility (University of Liège, Belgium). 
2.3. Antimicrobial Activity 
Antimicrobial  activity  was  assessed  with  a  colony 
overlay  assay  as  described  by  Barbosa  et  al.  (2005). 
Briefly,  overnight  cultures  of  BSP1  grown  in  LB 
medium were inoculated as a 5- L spot (to obtain giant 
colonies) on LB agar plates and incubated at 37°C for 24 
h prior to killing of the cells by exposure to chloroform 
vapors for 30 min. Plates were then aerated in a laminar 
flow hood for 20 min to allow the chloroform vapors to 
dissipate. Plates were finally overlaid with 0.7% LB or 
BH infusion agar seeded with an overnight culture of the Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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indicator  strain  listed  in  Table  1.  Zones  of  growth 
inhibition  of  the  indicator  stains  around  the  Bacillus 
giant colonies observed after 48 h of incubation at 37°C 
were scored as positive. 
2.4. Effect of Temperature, pH and Proteinase K 
on Antimicrobial Activity 
To evaluate protease sensitivity, purified subtilosin A 
(7 ng mL
-1) samples were analyzed by HPLC after 24 h 
of incubation at 37°C with proteinase K (Sigma-Aldrich, 
10 mg mL
-1 in 10 mM phosphate buffer, pH 7.2). Heat 
stability  was  evaluated  after  incubation  for  60  min  at 
various temperatures (30, 50, 75 and 100°C) whereas 
pH sensitivity was evaluated after one-hour incubation 
in 10 mM citrate buffer (pH 3), phosphate buffer (pH 
6)  and  CAPS  buffer  (pH  10).  After  treatments,  the 
remaining  subtilosin  A  activity  was  determined  by 
agar  diffusion  assay  using  Listeria  ivanovii  as 
sensitive strain (Halimi et al., 2010). 
2.5. Measurement of Transmembrane Electrical 
Potential 
Transmembrane  electrical  potential  (   ψ)  was 
monitored  using  the  fluorescent  dye  3,3’-
dipropylthiadicarbocyanine  iodide  (DiSC3  (5),  Anaspec, 
Fermont, CA, USA) as described elsewhere (Fickers et al., 
2009).  Briefly,  an  overnight  culture  of  L.  ivanovii  was 
pelleted by centrifugation and cells were resuspended in 
50mM HEPES buffer (pH 7) to obtain an A600 of 0.1 for 
the  cell  suspension.  DiSC3(5)  fluorophore  (1   M,  final 
concentration) was then added to 1 mL of cell suspension 
together  with  glucose  (10   M,  final  concentration)  and 
nigericin (1  M, final concentration, SigmaAldrich). After 
stabilization  of  the  fluorescence  signal  (excitations  and 
emission wavelengths were set at 622 nm and 670 nm, 
respectively),  purified  subtilosin  A  (10  ng  mL
-1)  was 
added and the change of fluorescence was monitored by 
using  a  LSB50  spectrofluorimeter  (Perkin-Elmer, 
Waltham, MA, USA). Finally, the ionophore valinomycin 
(1 M, final concentration, Sigma-Aldrich) was added to 
dissipate any residual  ψ. Stock solutions of DiSC3(5) (1 
mM),  glucose  (10  mM),  nigericin  (1  mM)  and 
valinomycin (1 mM) were freshly prepared before use. 
2.6. Disruption of Sbo Operon in BSP1 
Primer pairs sbo1-sbo2 and sbo3-sbo4 were designed 
for  the  amplification  of  ~700  bp  fragments 
corresponding to the up- and downstream region of the 
sboAX  locus  (ORFs  A7A1_01574  and  A7A1_01575). 
PCR  fragments  were  then  SfiI  digested,  purified  and 
ligated to a chloramphenicol resistance cassette rescued 
from  pRFP121  (Fickers,  unpublished)  after  SfiI 
digestion. The disruption cassette was then amplified by 
PCR using primer pair sbo1-sbo4, purified and used to 
transform BSP1 and B. subtilis 168 according to Kunst 
and  Rapoport  (1995).  Transformants  were  selected  on 
LB-chlorampenicol  plates  (5   g  mL
-1)  and  correct 
gene disruption was verified by analytical PCR using 
primer  pair  sbo1-sbo4.  A  ~1.7  kb  fragment  was 
obtained for wild-type genotype  whereas a ~ 2.5 kb 
fragment  was  obtained  for  the   sboAX  strain.  For 
those  latter,  loss  of  subtilosin  A  production  was 
verified either by RP-HPLC analysis and L. ivanovii 
growth  inhibition  test  (Halimi  et  al.,  2010).  The 
resulting  strains  were  denominated  BSP1 sboAX  and 
168 sboAX, respectively.  
2.7.  Construction  of  sbo-cfp  Transcriptional 
Fusion 
To  construct  a  fusion  of  the  sbo  promoter  to  cfp 
(coding for a cyan fluorescent protein), a ~ 420bp DNA 
fragment comprising the promoter region of sboA (ORF 
A7A1_0154), its start codon (ATG) and the first 38bp of 
its coding  sequence,  was  first amplified by PCR  from 
chromosomal  DNA  of  strains  B.  subtilis  PY79  and 
BSP1,  using  primers  sboA-380F,  which  generated  a 
KpnI restriction site and sboA-CFP+38R (containing a 
tail for cfp). Next, the cfp was amplified from pDR200 
(Doan  et  al.,  2005),  using  primers  CFP-24F  and 
CFP+750R,  which  generated  a  BamHI  restriction  site. 
An overlapping PCR was then performed between both 
DNA  fragments  using  primers  sboA-380F  and 
CFP+750R,  yielding  a  ~1200bp  DNA  fragment  that 
carried a KpnI restriction site at the 5´ end and a BamHI 
restriction site at the 3´ end. The KpnI-BamHI digested 
PCR fragments were inserted into pMS38 (Serrano and 
Henriques,  unpublished)  at  its  unique  restriction  sites 
KpnI  and  BamHI,  yielding  pCS57  and  pCS58.  The 
resulting  PsboA-cfp  transcriptional  fusions  were  then 
integrated at the sboA locus of strains PY79 and BSP1, 
creating strains AH7496 and AH7497, respectively. 
2.8. Fluorescence Microscopy 
For visualization of the PsboA-cfp fluorescence signal, 
600   L  of  LB  bacterial  cultures  were  removed  at  the 
appropriated times, centrifuged 30 seconds at 6000 rpm 
and resuspended in 200  L of PBS buffer. 2  L of cell 
suspensions  were  mounted  on  agarose  pads  (1.7%  in 
H2O) before microscope observation. Phase contrast and 
fluorescence images were acquired with a Leica DMRA2 Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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Microscope  equipped  with  a  63X  magnification 
objective and a CoolSNAPTM HQ Photometrics camera 
(Roper  Scientific,  Tuscon,  AZ,  USA).  Images  were 
acquired with Leica FW4000 software and prepared for 
publication  using  Adobe  Photoshop.  Quantification  of 
the  CFP  signal  was  done  for  500  cells  of  each  strain 
using the ImageJ software (http://rsb.info.nih.gov/ij/). 
3. RESULTS 
3.1. Antibacterial Activity of BSP1 
The  biological  activity  of  BSP1  was  investigated 
toward an array of bacteria isolated from swine intestinal 
content. For that purpose, BSP1 was first grown for 24 h 
on  plates  as  giant  colonies  before  being  overlaid  with 
soft agar medium containing the different strains to be 
tested. As shown in Table 1, the antimicrobial activity of 
BSP1  was  specifically  directed  against  Gram-positive 
bacteria. Indeed, no growth inhibition could be observed 
around  the  Bacillus  giant  colonies  for  the  different 
Gram-negative  bacteria  tested.  Among  Gram-positive 
bacteria, both L. ivanovii isolates were found the most 
sensitive whereas the closely related food poisoning L. 
monocytogenes  was  weakly  sensitive.  Beside  this,  the 
growth  of  C.  perfringens,  the  most  common  bacterial 
agent  for  gas  gangrene,  was  also  inhibited  by  BSP1. 
Staphylococcus hyicus, a pathogen responsible for swine 
exudative  epidermidis,  was  also  found  sensitive, 
however in a lesser extend. 
3.2. Purification  and  Characterization  of  the 
Antimicrobial Compounds 
To  further  characterize  this  biological  activity,  the 
antimicrobial  compound  was  extracted  from  BSP1 
culture  supernatant  and  purified  by  reverse  phase 
chromatography. The loss of biological activity toward 
L.  ivanovii,  together  with  the  disappearance  of  the 
corresponding  peak  on  HPLC  chromatograms  upon 
protease treatment highlight the proteinaceous nature of 
the purified compound (data not shown). Incubation at 
different  pH  showed  that  the  purified  antimicrobial 
compound  was  more  stable  at  acidic  pH.  Indeed,  its 
stability  decreased  as  the  pH  value  was  increased, 
especially  at  alkaline  pH.  Exposure  to  increasing 
temperature  led  to  a  decreased  biological  activity, 
indicating  thus  that  the  antimicrobial  compound  is 
temperature sensitive (Fig. 1A). 
The  membrane  pore-forming  biological  mode  of 
action  of  the  purified  peptide  was  highlighted  by 
monitoring the released of potentiometric probe DiSC3 
(5) from preloaded L. ivanovii cells (Fig. 1B). A high 
fluorescence signal, comparable to that obtained with 
the  ionophore  valinomycin,  could  be  observed  upon 
addition  of  the  purified  peptide.  This  indicates  the 
disruption  of  the   ψ  following  the  formation  of 
transmembrane pore by the peptide. 
MALDI-TOF  mass  spectrometry  analysis  of  the 
purified antimicrobial compound gave a positive signal 
at  m/z  of  3400.527,  which  is  consistent  with  the 
molecular mass of the bacteriocin subtilosin A 3400 Da 
(Stein et al., 2004; Liu et al., 2012) (Fig. 1C). Signals 
observed at m/z 3422.565 and 3438.545 correspond to 
the Na+ and K+ adducts, respectively. 
3.3. Genetic Characterization 
Inspection  of  the  BSP1  genome  sequence  revealed 
the  presence  of  ORFs  (A7A1_0154  to  A7A1_0162) 
coding  for  products  with  a  high  level  of  sequence 
identity (> 95%) to those of the sbo-alb operon of strain 
168  (Fig.  2A).  This  suggested  that  BSP1  could 
synthesize the bacteriocin subtilosin A. To confirm this, 
we disrupted the A7A1_0154 and A7A1_0155 ORFs of 
the  subtilosin  A  cluster  encoding  the  subtilosin  A 
structural  gene  by  insertion  of  a  chloramphenicol 
resistance  cassette  (Fig.  2A)  and  repeated  the 
purification scheme. We found that both the eluted peak 
that contained the antimicrobial compound (Fig. 2B) and 
the  antilisterial  activity  were  lost  for  the   sboAX-
derivative  compared  to  the  parental  strain  (Fig.  2C). 
Similar results were obtained for a  sboAXderivative of 
B. subtilis 168 (data not shown). 
3.4. Control of Subtilosin a Production 
The level of subtilosin A production was quantified 
by RP-HPLC in culture supernatants of B. subtilis strain 
BSP1 and 168 grown for 16 h at 37°C. As shown in Fig. 
3A,  the  subtilosin  A  productivity  was  found  six  fold 
higher for BSP1 compared to the laboratory strain. To 
further  characterize  this  phenotype,  the  sbo-alb 
expression  was  quantified  in  both  strains.  For  that 
purpose,  a  transcriptional  fusion  of  the  sbo  promoter 
(Psbo)  to  a  Cyan  Fluorescent  Protein  (CFP)  and 
fluorescence microscopy were used to monitor promoter 
activity in the cell population. The fluorescence images 
in Fig. 3C show that more cells of BSP1 appeared to 
express Psbo-cfp in LB at the end of the logarithmic 
phase  of  growth,  compared  to  the  laboratory  strain. 
The  fraction  of BSP1 cells  expressing  Psbo-cfp  was 
almost  two  times  higher  (Fig.  3B)  and  the  average 
fluorescence  signal  was  also  higher  for  the  BSP1 
population (Fig. 3C) bottom panels.  Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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Fig. 1. Characterization of the antimicrobial compound produced by BSP1. Panel A shows the effect of pH (black) and temperature 
(grey) treatments on the stability of the purified peptide. Values are expressed in relative activity and 100% was set for the 
higher value of antilisterial activity (pH3 and 35°C, respectively). Values are mean of three independent repetitions and the 
standard deviations were less than 10%. Panel B shows the dissipation of the transmembrane electrical potential ( ψ). The 
arrow 1 indicates the addition of purified compound (20  L) to a DiSC3 (5) preloaded L. ivanovii cell suspension whereas 
arrow 2 indicate addition of the ionophore valinomycin (1  L). Values were normalized to the fluorescence signal obtained 
with the ionophore valinomycin under the same conditions. Panel C shows the matrix-assisted laser desorption ionization 
time of flight spectrum of the purified compound produced by BSP1 Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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Fig. 2.  Genetic characterization of the subtilosin gene cluster in BSP1. Panel A shows the structure of the sboA-alb cluster of BSP1, 
which codes for subtilosin A biosynthetic enzymes and confers immunity to the peptide. The cluster is also found at an 
equivalent locus in strain 168 (the percentage of similarity of the predicted products between the two strains is indicated as 
well as the coordinates relative to oriC for BSP1). Also shown is the structure of a mutant obtained by replacing the sboA 
and sboX genes by a chloramphenicol resistance determinant (bordered by the two vertical lines), with the black dotted lines 
showing the boundaries of the DNA fragments used for recombination. Panel B shows the RP-HPLC chromatogram of 
culture supernatant of BSP1 (solid line) and the BSP1 sboAX deletion mutant (doted line). Panel C shows the bactericidal 
activity of subtilosin A (3.5  g) purified from wild-type BSP1 strain or of control material purified in parallel from the 
 sboAX mutant against a lawn of L. ivanovii cells Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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Fig. 3. Comparison of subtilosin productivity and of sbo-alb expression in BSP1 and laboratory strain. Panel A shows the relative 
subtilosin A productivity (quantity of subtilosin A produced per unit of biomass) obtained after 18 of growth in LB medium. 
Values are mean of three repetitions. Standard deviations were not significant. Panel B shows the percentage of cells of the 
laboratory strain or BSP1 with detectable expression of PsboA-cfp. Panel C shows microscopic examination of cells of the 
laboratory strain or BSP1, entering stationary phase and expressing a PsboA-cfp fusion. The cells were observed by phase 
contrast (top) and fluorescence microscopy (middle) and the distribution of the signal quantified as a function of cell number 
(bottom panel) Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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Essentially the same results were found in cells grown 
in  sporulation  medium  (data  not  shown).  In  control 
studies,  expression  of  Psbo-cfp  was  abolished  by 
deletion  of  the  spo0A  gene  in  line  with  the 
requirement  for  Spo0A  for  the  production  of 
subtilosin A (Strauch et al., 2007) (data not shown). 
4. DISCUSSION 
Members of the genus Bacillus are known to produce 
a  wide  range  of  antimicrobial  substances,  including 
peptides,  lipopeptides  and  the  so-called  bacteriocins 
(Stein,  2005;  Fickers,  2012).  The  production  of  these 
compounds,  together  with  sporulation  capacity,  endow 
Bacillus with potent selective advantages to cope with its 
natural  ecological  niches.  Bacteriocin  are  ribosomally 
synthetized peptide that elicit bactericidal activity through 
a  transmembrane  pore-forming  mode  of  action  toward 
pathogens  such  as  L.  monocytogenes,  Streptococcus 
pyogenes or C. perfringens (McAuliffe et al., 2001). Their 
antimicrobial  activity,  their  non-toxicity  for  man  and 
animal  commensal  gut  microflora,  render  these 
metabolites  very  attractive  for  agro-food  and 
biopharmaceuticals  applications  (Galvez  et  al.,  2007). 
The primary purpose of this study was to characterize the 
antimicrobial  compound  produced  by  BSP1,  a  strain 
isolated from broiler gastrointestinal tract (Barbosa et al., 
2005). The present results clearly demonstrated that this 
compound correspond to the bacteriocin subtilosin A, a 
35  amino  acid  cyclic  peptide  first  isolated  from  B. 
subtilis  (Babasaki  et  al.,  1985)  and  subsequently  from 
Bacillus  amyloliquefaciens  (Sutyak  et  al.,  2008)  and 
Bacillus  atrophaeus  (Stein  et  al.,  2004).  This  unusual 
bacteriocin  is  characterized  by  the  presence  of  three 
cross-links between sulfur of cysteine and the α-carbon of 
the  two  phenylalanine  and  threonine,  which  are  distinct 
from  the  thioether  bridges  observed  in  lantibiotics.  This 
posttranslationally  generated  architecture  renders  the 
molecule  stable  at  extreme  pH  and  highly  resistant  to 
endoproteinases in physiological conditions. 
The  production  of  antimicrobials  by  probiotics  is 
considered one of the principal mechanisms that inhibits 
growth  of  pathogenic  microorganisms  in  the  gastro-
intestinal  tract  (Hong  et  al.,  2005).  These  include 
bacteriocin  and  bactriocin-like  inhibitory  substances. 
Some Bacillus species contained in commercial products 
were  shown  to  produce  antimicrobials.  B. 
polyfermenticus SCD carried in Bispan has been shown 
to  produce  the  proteasesensitive  and  heat-labile 
bacteriocin,  polyfermenticum,  active  against  Gram-
positive bacteria (Lee et al., 2001). In poultry studies, 
controlled trials have shown that oral administration of 
B.  subtilis  spores  reduced  infection  by  Samonella 
enterica  serotype  Enteritidis,  C.  perfringens  and 
Escherichia  coli  078:K80.  More  precisely,  B.  subtilis 
2335, known under the trademark BioPlus 2B, has been 
shown  to  produce  antibiotics  (Pinchuk  et  al.,  2001). 
Beside this, other studies demonstrated that PY79 spores 
given  to  day-old  chicks  24  prior  to  challenge  with  C. 
perfringens resulted in a significant reduction of gastro-
intestinal tract infection and fecal shedding (La Ragione 
and Woodward, 2003). However, subtilosin A, the main 
antimicrobial compound produced by PY79, was never 
been demonstrated responsible for this effect. 
The  higher  subtilosin  A  productivity  observed  for 
BSP1 compared to the laboratory strain 168 or PY79 was 
unexpected.  To  explain  this  observation,  we 
hypothesized that this particular phenotype could results, 
at least in part, from an increased expression of the sbo-
alb operon. Indeed, the production of mature subtilosin 
A is based on the expression of the sbo-alb gene cluster 
encompassing the subtilosin A structural gene sbo and 
the alb genes involved in posttranslational modifications, 
processing  of  presubtilosin  A  and  in  immunity 
mechanism (Zheng et al., 1999). The regulation of the 
sbo-alb expression is complex and related with the onset 
of  the  stationery  phase.  Induction  occurs  during  late 
growth  phase  in  response  to  carbon  sources  starvation 
and oxygen limitation (Nakano et al., 2000). Subtilosin 
A synthesis is negatively regulated by the transition state 
regulatory  protein  AbrB  which  binds  directly  onto  the 
sbo-alb  promoter  during  exponential  growth  phase 
(Strauch  et  al.,  2007).  When  cells  approach  the 
stationery  phase,  Spo0A,  the  stationary  phase  and 
sporulation master regulator is phosphorylated through a 
phosphorelay  signal  transduction  system  (Trach  et  al., 
1991).  The  first  step  is  the  ATPdependent 
autophosphorylation  of  protein  kinase  Kin  family  that 
feed  the  phosphate  group  into  the  phosphorelay. 
Accumulation of Spo0A-P led to the repression of abrB 
and thus to the derepression of sbo-alb operon. Recent 
investigations  highlighted  an  increased  sporulation 
capacity of BSP1 during growth and demonstrated that 
this phenomenon was the consequence of an increased 
activity of Spo0A in the cell population. Therefore the 
higher level of sbo-alb expression and thus subtilosin A 
productivity,  could  be  explained  by  this  increased 
activity of Spo0A in B. subtilis BSP1 compared to that of 
the laboratory strain B. subtilis 168 and PY79. Ghislain Schyns et al. / American Journal of Biochemistry and Biotechnology 9 (3): 307-317, 2013 
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5. CONCLUSION 
Through  this  study  the  gut-associated  B.  subtilis 
BSP1 has been demonstrated able to synthetize the cyclic 
bacteriocin  subtilosin  A  at  high  level  compared  to 
laboratory  strains.  Our  findings  suggest  that  the  BSP1 
phenotype  could  be  related  to  an  increased  expression 
level of the subtilosin A biosynthetic gene cluster sbo-alb 
in  response  to  a  higher  activity  of  the  stationery  and 
sporulation master regulator Spo0A. 
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